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http://dx.doi.org/10.1016/j.ccell.2014.10.003SUMMARYAlveolar soft part sarcoma (ASPS), a deadly soft tissue malignancy with a predilection for adolescents and
young adults, associates consistently with t(X;17) translocations that generate the fusion gene ASPSCR1-
TFE3. We proved the oncogenic capacity of this fusion gene by driving sarcomagenesis in mice from condi-
tional ASPSCR1-TFE3 expression. The completely penetrant tumors were indistinguishable from human
ASPS by histology and gene expression. They formed preferentially in the anatomic environment highest
in lactate, the cranial vault, expressed high levels of lactate importers, harbored abundant mitochondria,
metabolized lactate as a metabolic substrate, and responded to the administration of exogenous lactate
with tumor cell proliferation and angiogenesis. These data demonstrate lactate’s role as a driver of alveolar
soft part sarcomagenesis.INTRODUCTION
Approximately one-third of all sarcomas, the cancers of connec-
tive tissue, associate with chromosomal translocations that
generate fusion genes (Helman andMeltzer, 2003). Many of these
fusion genes have been shown to serve as primary drivers of sar-
comagenesis (Haldar et al., 2007;Keller et al., 2004;Pe´rez-Losada
et al., 2000; Straessler et al., 2013). Alveolar soft part sarcoma
(ASPS), a deadly soft tissue malignancy of enigmatic origin,
consistently demonstrates a t(X;17)(p11.2;q25) translocation that
produces the fusion gene ASPSCR1-TFE3 (Ladanyi et al., 2001).
ASPS presents most frequently in the adolescent or young
adult limb, often metastasizes, and generally proves resistantSignificance
By conditionally expressing in mice the fusion gene ASPSCR
generated a model that recapitulates the human tumor histolo
ditions supportive of tumor development. Mouse tumors demo
hypoxia and were restricted to the tissue compartments highe
proteins (MCT1s) and responded to exogenous lactate with rob
in a malignancy has been previously postulated, but never bef
esismodel. Interventions targeting lactatemetabolismmay pro
Cato chemotherapy (Folpe and Deyrup, 2006). First described in
1951 (Smetana and Scott, 1951), these highly vascular tumors
demonstrate characteristic histomorphology, comprised of or-
ganoid nests of polygonal tumor cells separated by fibrovascular
septa with delicate capillary arcades (Folpe and Deyrup, 2006).
ASPSs also demonstrate distinct, granular structures in the cyto-
plasm of some cells (Ladanyi et al., 2002).
Using the few available cell lines and analysis of human ASPS
tumor specimens, it has been shown that the ASPSCR1-TFE3
fusion protein functions as a master regulatory transcription
factor, joining a yet-to-be deciphered activation motif from
ASPSCR1 to the DNA-binding domain of the TFE3 transcription
factor from the MITF family (Covell et al., 2012; Kummar et al.,1-TFE3 from human alveolar soft part sarcoma (ASPS), we
gically and by expression profile, enabling study of the con-
nstrated angiogenic gene expression in the frank absence of
st in lactate. They expressed high levels of lactate transport
ust proliferation and angiogenesis. Such lactatemetabolism
ore available for direct investigation in an in vivo tumorigen-
vide therapeutic approaches for this and othermalignancies.
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Figure 1. A Mouse Allele with Conditional
Expression of Human ASPSCR1-TFE3
(A) Schematic demonstrating generation of the
fusion transcript in human alveolar soft part sar-
coma, which was reverse transcribed to a com-
plementary DNA (cDNA) and targeted to the
Rosa26 locus, separated from its promoter by
a loxP-flanked stop sequence consisting of the
neomycin resistance gene (neoR) and a poly-
adenylation transcription termination sequence.
The cDNA is followed by enhanced green fluo-
rescent protein (eGFP) and an internal ribosomal
entry site (IRES), such that both the fusion gene
and eGFP will be translated from the same tran-
script following Cre-mediated recombination to
remove the stop.
(B) Photomicrographs of embryonic day 12.5
Rosa26LSL-AT3/WT fibroblasts 48 hr after exposure
to TATCre or control, demonstrating GFP fluo-
rescence from the recombined allele.
(C) RT-PCR showing presence of the fusion gene
transcript following TATCre, but not control. Scale
bars represent 100 mm.
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Alveolar Soft Part Sarcomagenesis in the Mouse2013; Ladanyi et al., 2001; Stockwin et al., 2009). Although many
angiogenic genes are highly upregulated in the tumors (Lazar
et al., 2007; Vistica et al., 2009), few were found to be direct
transcriptional targets of the fusion protein by chromatin immu-
noprecipitation analyses (Kobos et al., 2013). This suggests
that some other factor, possibly related to metabolism or micro-
environment, enhances angiogenesis in ASPS. We exploited an
in vivo oncogenesis model to investigate.
RESULTS
Generation of an Inducible Mouse Allele of
ASPSCR1-TFE3
In order to characterize the fusion gene associated with ASPS
and its role in sarcomagenesis, we created a mouse allele
designed to express ASPSCR1-TFE3 conditionally. Briefly, the
Rosa26-LSL-AT3 allele was generated by isolating the type 2
ASPSCR1-TFE3 fusion gene transcript from total RNA obtained
from a human ASPS. The complete complementary coding
sequence (cDNA) was placed in the Rosa26 locus separated
from the native promoter by a stop sequence, flanked by loxP
sites (LSL), that is conditionally removed via Cre-mediated
recombination. The fusion gene cDNA was followed by
coding sequence for the enhanced green fluorescent protein
(eGFP), linked by an internal ribosomal entry site (IRES) to852 Cancer Cell 26, 851–862, December 8, 2014 ª2014 Elsevier Inc.permit tandem expression of eGFP
whenever ASPSCR1-TFE3 was ex-
pressed (Figure 1A).
To validate the conditional character of
the LSL-AT3 allele, heterozygous E12.5
fibroblasts were harvested, dissociated,
and cultured, then exposed either to
vehicle control or TATCre, a protein
version of Cre-recombinase with the
TAT moiety from the human immuno-
deficiency virus that enables transportthrough the cell membrane and localization to the nucleus (Joshi
et al., 2002; Straessler et al., 2013). After 48 hr, cells exposed
to TATCre, but not control conditions, fluoresced (Figure 1B).
RT-PCR also confirmed the presence of the fusion gene tran-
script following Cre-mediated recombination (Figure 1C).
ASPSCR1-TFE3 Expression Leads to Rapid,
Anatomically Restricted Tumorigenesis
Considering possible tumorigenesis in a comparative context,
mice homozygous for conditional AT3, as well as other mice
homozygous for previously described conditional SS18-SSX2
(synovial sarcoma) (Haldar et al., 2007) and EWSR1-ATF1 (clear
cell sarcoma) (Straessler et al., 2013) were bred to mice bearing
a tamoxifen-inducible Cre-recombinase also driven from the
Rosa26 locus (Mao et al., 1999). It has been previously noted
that in the absence of tamoxifen, a small portion of cells in
most tissues in the mouse will undergo Cre-mediated recombi-
nation from nuclear entry of the CreER (Haldar et al., 2007;
Straessler et al., 2013). We used it in this fashion as a low-prev-
alence, but random tissue initiator of expression.
In the comparative cohorts, Rosa26-LSL-EWSR1-ATF1/CreER mice
demonstrated clear cell sarcoma mimicking tumors across
a broad anatomic distribution in the 3–6 month age range.
Rosa26-LSL-SS18-SSX2/CreER mice manifested a similar anatomic
distribution of synovial sarcoma mimicking tumors, but following
Figure 2. ASPSCR1-TFE3 Induces Rapid Tumorigenesis Restricted
to the Cranium
(A) Chart depicting the relative rates of tumorigenesis among
Rosa26-LSL-EWSR1-ATF1/CreER, Rosa26-
LSL-SS18-SSX2/CreER, and
Rosa26-LSL-AT3/CreER mice.
(B) Diagrams of the anatomic distribution of tumors among
Rosa26-LSL-EWSR1-ATF1/CreER, Rosa26-
LSL-SS18-SSX2/CreER, and
Rosa26-LSL-AT3/CreER mice.
(C–K) Lateral cranium radiographs (C and D), gross dissection midsagittal brain
photos (E and F), and GFP fluorescence photos (G and H) of 3-month-old
Rosa26-LSL-AT3/CreER (C, E, and G) and Rosa26-
LSL-AT3/WT (D, F, and H) mice
showing occipital expansion (between black arrows, C) from a tumor that
developed in the brain (white arrows, E and G) and demonstrates GFP fluores-
cence from the active AT3 allele. Representative photomicrographs of the
gamut of intracranial tumor presentations inRosa26-LSL-AT3/CreERmice, inwhich
most were intraparenchymal (I), but one encroached on the choroid plexus (J)
and another developed within the eye (K). Scale bars represent 500 mm.
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developed either unusual behavior or a visibly enlarging occiput
between 3 and 6 months of age. On necropsy, every mouse
was noted to have developed a tumor within the skull (Figures
2A and 2B).
Rosa26-LSL-AT3/CreERmice often demonstrated enlargement of
the occipital bone from inner soft tissue expansion (Figures 2C
and 2D). Slightly pink colored tumors (Figures 2E and 2F) were
found primarily in the brain parenchyma, but also in the choroid
plexus and orbit (Figures 2I–2K). The AT3-induced tumors
fluoresced (Figures 2G and 2H), indicating eGFP and therefore
fusion gene expression.
Mouse Tumors from ASPSCR1-TFE3 Mimic Human
ASPS Histopathology
We next determined whether or not the tumors induced by the
conditional AT3 allele recapitulated human ASPS histopatholog-Caically. Hematoxylin and eosin (H&E) staining of a panel of human
ASPS and Rosa26-LSL-AT3/CreER mouse tumors demonstrated
the characteristic nests of polygonal cells with an open chro-
matin pattern, surrounded by neatly arcading capillary and larger
vascular channels (Figures 3A–3D). The species of origin for each
slide was microscopically indistinguishable by an expert sar-
coma-focused pathologist.
Diastase treatment of sections followed by periodic acid Schiff
(dPAS) histochemical staining produces a pathognomic pattern
in ASPS. In mouse tumors, dPAS demonstrated the character-
istic granular deposits classically described in human ASPS (Fig-
ures 3E and 3F).
Many clinical laboratories use immunohistochemical staining
against TFE3 as a surrogate marker for the fusion (Argani et al.,
2003). We submitted human ASPS, Rosa26-LSL-AT3/CreER, and
Rosa26-LSL-SS18-SSX2/CreER tumor sections to our clinical labora-
tory. Both human andmouse tumors associated withASPSCR1-
TFE3 demonstrated the diagnostic, strong nuclear TFE3 staining
(Figures 3G and 3H), whereas mouse tumors driven by SS18-
SSX2 provided the appropriate negative control (data not
shown).
Tumors induced by conditional AT3 expression in the mouse
often arose in or near the leptomeninges, along sulci (Figure 3I).
Some tumors showed a broad, pushing front that maintained the
pia mater layer between tumor and surrounding brain paren-
chyma (Figure 3J). Others demonstrated more aggressive inva-
sive growth, with distinct extensions of tumor cells into the
cerebellum, cerebrum, and the vessels of the choroid plexus
(Figures 3K–3M). Invasive foci were often invested with capil-
laries (Figure 3N), which may represent tumor-induced vessels
or microvascular invasion.
The ASPSCR1-TFE3-Driven Mouse Tumor
Transcriptome Mimics Human ASPS
In order to further validate the tumors generated by conditional
AT3 expression as a model for human ASPS, we performed a
series of transcriptomic analyses. Iterative alignment of gene
expression profiles between mouse and human tumors from
multiple series has proven fruitful in the past to identify the
unique expression signature of a given tumor type (Haldar
et al., 2007). Such analyses are best performed with a common
control tissue as a sounding board or background for each tumor
transcriptome. Becausemost human ASPSs arise within skeletal
muscles, and high quality muscle samples could be obtained
from both mice and humans, we selected skeletal muscle as
our comparative control, even though it was clear that themouse
tumors did not arise from muscle.
Sequencing of cDNA libraries prepared from total RNA
(RNAseq) from five histologically and translocation-confirmed
human ASPSs, three human skeletal muscle samples, five
Rosa26-LSL-AT3/CreER-induced mouse tumors, and three mouse
skeletal muscle samples yielded species-specific alignments
that could be compared after filtering and reassigning mouse
genes onto human homologs. Cross-species gene set enrich-
ment analysis (GSEA) was then performed for the 500 most
significantly upregulated and 500 most significantly downregu-
lated genes in each intraspecies tumor to muscle comparison.
In both directions, GSEAs showed strong and significant enrich-
ment for the upregulated gene sets (false discovery rate [FDR]ncer Cell 26, 851–862, December 8, 2014 ª2014 Elsevier Inc. 853
Figure 3. ASPSCR1-TFE3-Induced Mouse
Tumors Recapitulate Human Alveolar Soft
Part Sarcoma Diagnostic Histopathology
(A–D) Low-power (A) and high-power (B) hema-
toxylin and eosin photomicrographs from tumors
arising in Rosa26-LSL-AT3/CreER mice match those
from human ASPSs (C and D) in the overall tissue
architecture of loosely nesting cells between
arcading capillary networks and cellular features
of round large nuclei with prominent nucleoli.
(E and F) Photomicrograph of diastase-resistant
periodic acid Schiff staining identifies the patho-
gnomonic cytoplasmic granules (black arrows)
in Rosa26-LSL-AT3/CreER mouse tumors (E) and
human ASPSs (F).
(G and H) Clinical immunohistochemistry against
human TFE3 demonstrates strong nuclear stain-
ing in bothRosa26-LSL-AT3/CreERmouse tumors (G)
and human ASPSs (H).
(I–N) H&E photomicrographs demonstrate a tu-
mor growing between sulci near the investing pia
mater (arrows in I), which was sometimes main-
tained between the tumor cells and the sur-
rounding tissues (arrows in J); other invading
tumor cells into the cerebellum (K), cerebral cor-
tex (L), and choroid plexus (M) maintained no
intervening leptomeningeal layer, but often asso-
ciated closely with small vessels (arrows in N). All
scale bars and the width of (B) and (D)–(F) repre-
sent 40 mm.
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downregulated gene sets (FDR q value = 1.0 for all) (Figure 4A).
This was repeated for the second through fifth groups of 500
most upregulated genes from the human RNAseq comparison
in the mouse samples, such that all genes at least 2-fold signifi-
cantly upregulated were tested. All five of these gene sets were
significantly enriched in themouse tumor tomuscle gene ranking
with a normalized enrichment score (NES) of >1.8 and an FDR q
value of <0.0005 for each. Such enrichment of homologous
genes suggests a strong transcriptomic match between the
mouse model and human ASPS.
For an external validation, microarray-derived expression pro-
files on the Affymetrix Human Genome U133 Plus 2.0 Array from
seven human ASPSs and five human skeletal muscle control
samples were obtained from the Gene Expression Omnibus
(GEO) records GSE13433 and GSE34111. Each list of upregu-
lated genes was significantly enriched by GSEA in comparison
across species and RNAseq versus microarray platforms (FDR
q value < 0.0005 for each). Each list of downregulated genes
showed no enrichment (FDR q value = 1.0 for each) (Figure 4A).
As a second external validation, we evaluated the expression of
the 51 human genes found by Kobos et al. (2013) to be upregu-
lated in multiple human series and whose promoters were found
to be bound by the fusion oncoprotein in chromatin immunopre-
cipitation experiments. Forty-five of these genes were at least
1.5-fold upregulated in mouse tumors compared to mouse
muscles.854 Cancer Cell 26, 851–862, December 8, 2014 ª2014 Elsevier Inc.In order to determine a species tran-
scendent ASPSCR1-TFE3 gene expres-
sion signature, we identified all humangenes or mouse homologs that were at least 2-fold upregu-
lated and statistically significant (p < 0.05) in all three tumor
to muscle comparisons (Table S1 available online). A heatmap
of these 539 unique genes, contrasting log2 transformed
fold-changes of tumors versus controls (Figure 4B) showed
consistently high expression across individual tumor samples
from each group. Finally, assessment of the character of
these consistently upregulated genes by GO-Elite analysis
noted carbohydrate metabolism, cell division, and cell cycle
as the most significant biological process gene ontologies
(Figure 4C).
ASPSCR1-TFE3 Expression Leads to Spatially
Restricted Tumorigenesis Even among Different Cell
Lineages
The observation that tumors in Rosa26-LSL-AT3/CreER mice
recapitulated human ASPS features so clearly by histopathol-
ogy and transcriptomic analysis only enhanced our notice
of the difference between the two species in anatomic
distribution. Whereas most human ASPSs arise in skeletal
muscle, none of the Rosa26-LSL-AT3/CreER mice developed
tumors in the skeletal muscle. This contrasted with our com-
parison mouse genetic cancer models that actually favored
development of tumors within skeletal muscles, despite
expressing their respective fusion genes from the identical
locus and initiated by the same driver of Cre-recombinase
(Figure 2B).
Figure 4. ASPSCR1-TFE3-Induced Mouse
Tumors Recapitulate Human Alveolar Soft
Part Sarcoma by Transcriptome Profile
(A) Series of Broad Institute gene set enrichment
analysis (GSEA) plots testing the 500 most
significantly upregulated (left, in each pair) and
downregulated (right, in each pair) genes from the
Rosa26-LSL-AT3/CreER mouse tumor (mASPS) to
muscle RNAseq comparison, the human alveolar
soft part sarcoma (hASPS) to muscle RNAseq
comparison, and the human ASPS to muscle
microarray comparison (GEO), in each of the
other data sets. All of the upregulated gene lists
had high normalized enrichment scores (NES)
and were statistically significant with false
discover rate q values < 0.0005. None of the
downregulated gene lists showed enrichment.
(B) Heat map of log2 transformed fold-changes
from the control mean of the 539 genes with at
least 2-fold and significant mean upregulation in
all three data sets.
(C) Chart of the Z scores of the most significant
biological process gene ontologies from GO-Elite
analysis of the 539 genes upregulated in all three
data sets.
See also Table S1.
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cell of origin for transformation by AT3 expression, leading to
tumorigenesis that was too rapid to allow slower limb tumors
to become detectable, we next crossedmice bearing conditional
AT3 with mice bearing a lineage-restricted tamoxifen-inducible
Cre-recombinase, expressed from a Prx1 promoter (Prx1-
CreERT2) (Hasson et al., 2007). Prx1-CreERT2 mice have a
well-documented lineage that emphasizes osteochondral pro-
genitors in the periosteal mesenchyme, but also includes some
intramuscular pericytes (Kawanami et al., 2009; Logan et al.,
2002; Straessler et al., 2013). Prx1-CreERT2;Rosa26LSL-AT3/WT
mice consistently developed intracranial tumors 10–14 weeks
after tamoxifen at age 2 weeks. Interestingly, tumors were
located either within the brain parenchyma or in the periosteum
along the inner table of the cranium (Figure 5A). No tumors were
identified in the outer table periosteum or the limbs, where most
of the postnatal Prx1 lineage is found.Cancer Cell 26, 851–862, DPrx1 expression in neural stem cells
has been previously described (Shimo-
zaki et al., 2013). We have also previously
shown the lineage to include perivascu-
lar mesenchymal cells (Straessler et al.,
2013). Either of these portions of the
Prx1 lineage might explain the intrapar-
enchymal tumors, but the periosteal
tumors presented a conundrum. First,
these periosteal cells of origin were
decidedly not within the brain paren-
chyma, ruling out our initial suspicion
of a preferred cell of origin in that host
tissue. Second, the periosteal lineage
(including mesenchymal progenitors to
both osteochondral and endothelial dif-ferentiation) should not be different morphologically on the inner
surface of the cranium than outside the cranium.
To compare the presence of the lineage on the inner table of
the cranial periosteum, we crossed Prx1-CreERT2 bearing
mice to mice bearing a Rosa26-LSL-LacZ reporter allele
(Soriano, 1999). X-gal staining of 3-week-old Prx1CreERT2;
Rosa26LSL-LacZ/WT mouse brains post receipt of tamoxifen at
2 weeks demonstrated periosteal staining along the inner and
outer tables of the cranium as well as in the limb periosteum
(Figure 5B).
Notably, the extracranial periosteum stained just as consis-
tently as did the intracranial periosteum with lineage tracing,
but only the latter gave rise to tumors in Prx1CreERT2;
Rosa26LSL-AT3/WT mice. The spatially restricted development of
periosteal tumors intra- but not extracranially suggested that
something unique to the microenvironment inside the cranial
vault enhanced at least the efficiency of tumorigenesis there.ecember 8, 2014 ª2014 Elsevier Inc. 855
Figure 5. ASPSCR1-TFE3-Induced Tumori-
genesis Is Most Efficient within the
Cranium
(A) Diagram depicting the relative incidence and
representative histopathology of the two grouped
anatomic locations of tumors arising between
ages 13 and 16 weeks among 6 Prx1-CreERT2;
Rosa26-LSL-AT3/WT littermate mice after receiving
tamoxifen at age 2 weeks.
(B) Photomicrographs of X-gal-stained sections
from the cranium’s inner and outer tables, as well
as the proximal humerus in 3-week-old Prx1-
CreERT2;Rosa26-LacZ/WT mice after receiving
tamoxifen at age 2 weeks, demonstrating the
Prx1-CreERT2 lineage in each location (blue cells
identified by black arrows), only the first of which
led to identifiable tumorigenesis when initiating
theAT3 allele. Scale bars in (A) and panel widths in
(B) represent 100 mm.
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To triangulate our thinking about the microenvironment pertinent
to intracranial mouse tumors and human ASPSs in skeletal mus-
cle, we returned to what both species’ tumors had in common:
deranged carbohydrate metabolism (Figure 4C). Both brain
and muscle have been the primary tissues of focus in the eluci-
dation over recent decades of the phenomenon termed lactate
flux (Brooks and Gaesser, 1980; Gladden, 2008). Some cells
either temporarily or consistently export lactate produced by
glycolysis. Other cells (in nearby or distant tissues accessed
through the circulation) import andmetabolize that lactate. While
muscle can demonstrate a high volume lactate flux during activ-
ity, the brain consistently moves lactate between cells via the
astrocyte-neuron shuttle (Aubert et al., 2005).
Significant lactate import requires elevated interstitial or
intravascular lactate and the expression of monocarboxylate
transporters (MCTs). Although lactate can cross membranes
via other means, MCTs are responsible for the bulk of lactate
transport. MCT1 and its binding partner CD147 are highly ex-
pressed in tissues that primarily import lactate; MCT4 is highly
expressed in tissues that primarily export lactate (Halestrap,
2013).
We assessed the raw RNAseq expression levels (in fragments
per kilobase of exon per million fragments mapped or FPKM
units) of monocarboxylate transport genes in tumors and mus-
cles. The muscle provided an ideal comparison control tissue,
as skeletal muscle is known to express high levels of lactate
transport genes. The two genes comprising the lactate transport
complex associated with lactate importation, Mct1 and Cd147,
were highly overexpressed in tumors compared to muscles or856 Cancer Cell 26, 851–862, December 8, 2014 ª2014 Elsevier Inc.compared to any other monocarboxylate
transport genes in the tumors (Figure 6A).
This fit the previously reported immuno-
histochemical finding of these two pro-
teins in the cytoplasmic crystals stained
by dPAS in human ASPS (Ladanyi et al.,
2002). Further, Mct4, the transport gene
associated with lactate exportation, was
not only expressed at a much lower levelin tumors than the import-associated complex, but also at a
significantly lower FPKM than in muscle.
MCTs are not pumps; their function requires lactate available
for import. We therefore biochemically measured the lactate
concentration in a panel of tissues in normal 2-month-old
mice. Brain and eye, the host tissue compartments of all the
AT3-driven tumors, demonstrated the highest tissue lactate
concentrations (Figure 6B).
Lactate Serves as a Metabolic Substrate in
ASPSCR1-TFE3 Tumors
In order for imported lactate to contribute to metabolism, the cell
would have to have significant oxidative capacity. As a measure
of the abundance of mitochondria, we examined the expression
of genes coding for proteins confirmed to locate within mito-
chondria, using the Broad Institute’s MitoCarta list. Again, the
comparison control of muscle was fortuitous in that muscle
exhibits one of the highest mitochondrial contents in normal
mammalian tissues. Surprisingly, ASPSCR1-TFE3-driven tu-
mors demonstrated upregulation of nearly the entire comple-
ment of mitochondrial genes compared to quadriceps muscle
controls, in both mouse and human comparisons (Figures 7A
and 7B).
We also measured the oxygen consumption of fresh tissue
sections from AT3-driven mouse tumors compared to other
tumor controls, both at baseline in minimal media and
following administration of lactate substrate. ASPSCR1-TFE3-
driven mouse tumors were more oxidative than comparison
mouse tumor types at baseline and responded oxidatively to
the administration of lactate substrate (Figures 7C and 7D).
Figure 6. ASPSCR1-TFE3-Induced Mouse
Tumor Lactate Transport Gene Expression
and Tissue Lactate Levels in the Mouse
(A) Chart of the gene expression by fragments per
kilobase of exon per million fragments mapped
(FPKM) in Rosa26-LSL-AT3/CreER mouse tumors
(black) and muscle samples (red), showing high
and significantly upregulated expression of both
Cd147 and Mct1 in tumors and low and signifi-
cantly downregulated expression of Mct4.
(B) Plot of the individual (dots) and mean (bars)
concentrations of lactate in the tissues of five
mice, determined biochemically.
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TFE3 Tumors
While considered to be induced by hypoxia through downregu-
lation of its hydroxylation and proteasomal degradation at low
oxygen levels, HIF1a also directly responds to lactate levels
within a cell (Figure 8A) (Burns and Wilson, 2003; Kumar et al.,
2007; Xiong et al., 1998). Needless to say, this phenomenon con-
tributes to the hypoxic stabilization of HIF1a, as intracellular
lactate accumulates in hypoxia, but does not strictly require hyp-
oxia itself.
It has been previously shown that human ASPS has high levels
of HIF1a (Kenney et al., 2011; Stockwin et al., 2009; Vistica et al.,
2009). If these levels were generated in response to imported
lactate, as opposed to lactate produced within the cell, they
should be independent of hypoxia. We quantitated the level of
hypoxia within the tumors by administering pimonidazole to tu-
mor-bearing Rosa26-LSL-AT3/CreER mice prior to euthanasia.
Only in the presence of hypoxia (oxygen tensions lower than
10 torr) will pimonidazole form adducts with thiol groups that
are detectable by immunohistochemistry with an available
monoclonal antibody (Rosenberger et al., 2009).
Control tissues of the kidney, liver, brain, and skin were
collected as well as tumors from each mouse. While the normal
prevalence of pimonidazole adducts and therefore hypoxia was
detected in each of the control tissues, few tumors demon-
strated any hypoxia (Figure 8B). Tumors demonstrated less hyp-
oxia than even the surrounding normal brain parenchyma.
Normal tissues showed demonstrable Hif1a immunohisto-
chemistry only in hypoxic regions, such as the renal tubules. In
contrast, tumors demonstrated strong nuclear Hif1a staining
throughout (Figure 8B), despite normoxia. Signaling from im-
ported lactate can increase levels of Hif1a in normoxia. We
further tested these thoroughly nonhypoxic tumors for expres-
sion of a ‘‘hypoxic’’ gene signature and found them to demon-
strate enrichment (Figure 8C), possibly reflecting other indirectly
lactate-responsive genes.
In order to test the hypothesis that ASPSCR1-TFE3 tumors
receive signaling from imported lactate, we administered lactate
or saline by daily isotonic intraperitoneal (i.p.) injections for
2 weeks prior to sacrifice in a subset of mice that had developed
tumors. Exogenous lactate drove increases in proliferative index
and vascular density (Figure 8D-F). As cross-validation of this ef-
fect, we cultured the only two described human cancer cell linesCathat express ASPSCR1-TFE3, FU-UR-1 (Ishiguro et al., 2004;
Kobos et al., 2013) and ASPS-1 (Kenney et al., 2011) in
increasing concentrations of sodium lactate, identifying a prolif-
erative response. We further confirmed that increased exoge-
nous lactate concentration in normoxia drove higher HIF1a
stabilization, evidenced by its increased nuclear presence. This
effect was blocked by tandem application of a-cyano-4-hydrox-
ycinnamate (CHC), a chemical inhibitor of MCT1.
DISCUSSION
We report a genetic model of alveolar soft part sarcomagenesis
and have validated its mimicry of human tumors with both histo-
logic and transcriptomic analyses. This model revealed an un-
usual anatomic distribution, which has implications with regard
to cell of origin and the metabolic microenvironment. Despite
the already reported high expression of Hif1a and proangiogenic
genes in ASPS, we demonstrated that these tumors lack frank
hypoxia. When provided exogenous administration of lactate,
the tumors responded with enhanced proliferation and angio-
genesis, suggesting that lactate, not hypoxia, contributes to
this unique form of sarcomagenesis.
Previously, members of our group have demonstrated the
oncogenicity of the fusion genes that derive from chromosomal
translocations in alveolar rhabdomyosarcoma (PAX3-FKHR)
(Keller et al., 2004), synovial sarcoma (SS18-SSX2) (Haldar
et al., 2007), and clear cell sarcoma (EWSR1-ATF1) (Straessler
et al., 2013). Others have shown a similar transformation in the
mouse by the FUS-CHOP fusion oncogene associated with
myxoid liposarcoma (Pe´rez-Losada et al., 2000). By using a
Cre/loxP conditional construct in the Rosa26 locus to drive
expression of ASPSCR1-TFE3, we have now shown this fusion
gene to be sufficient for completely penetrant oncogenesis in
the mouse.
The AT3-driven mouse tumors were histopathologically well-
matched to human ASPS, demonstrating the prototypical,
classic features. Expression profiles were also stridently parallel
between mouse and human tumors. Such interspecies compar-
isons have been fraught with difficulty in the past. We have pre-
viously utilized RNAseq as a less platform-constrained means
of understanding the transcriptome of mouse tumor models
(Straessler et al., 2013), but never before had human tumor
RNAseq data for comparison, as we had in these analyses. Inncer Cell 26, 851–862, December 8, 2014 ª2014 Elsevier Inc. 857
Figure 7. ASPSCR1-TFE3-Induced Mouse Tumors and Human
Alveolar Soft Part Sarcomas Can Metabolize Lactate
(A and B) Heat maps from Rosa26-LSL-AT3/CreER mouse tumors (A) and human
alveolar soft part sarcomas (B) showing the log2 ratios of expression
normalized to the mean for the Broad Institute’s curated MitoCarta gene list.
(C) Chart of the mean ± SD of the oxygen consumption rate (normalized by
DNA content) of tissue sections from tumors arising in mice induced by each of
three fusion oncogenes, representing alveolar soft part sarcoma, synovial
sarcoma, and clear cell sarcoma (n = 10 for each).
(D) Chart of the mean ± SD of the percent change in oxygen consumption
among fresh tissue sections from three mouse tumor types upon administra-
tion of 10 mM lactate substrate (n = 5 for each).
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array-based study of human ASPS gene expression and another
chromatin immunoprecipitation analysis to further validate our
primary RNAseq results.
Taken together, these results from both gene expression and
histopathology argue that in a manner similar to synovial sar-
coma and clear cell sarcoma, the complicated biology of ASPS
initiation is recapitulated by mere expression of its fusion gene
ASPSCR1-TFE3. Importantly, none of these genetic mouse
models driven by expression of translocation-generated fusion
oncogenes fully recapitulates the most advanced clinical stages
of its related human sarcoma. In addition to the lack of overt
metastases, shared by all of the above models, this ASPS
model also lacks histologically clear vascular invasion, which is
commonly identified in the human counterpart, but complicated
by the intracranial location of the mouse tumors. Possibly, such
aggressive features of disease require more time or larger tumor858 Cancer Cell 26, 851–862, December 8, 2014 ª2014 Elsevier Inc.size than can be endured by mice, but notably, this emphasizes
that the biology modeled is that of sarcoma initiation rather than
advanced clinical disease.
While the cell of origin of this unique tumor has long been
controversial, our studies lend some insights to the debate. Prior
arguments have typically centered on either a myogenic or neu-
ral cell of origin, depending on gene expression in tumors as
evidence of histogenesis. The formation of mouse tumors in
intracranial tissue compartments that completely lack skeletal
muscle removes the possibility of an exclusively skeletal muscle
cell of origin. Of course, the same can be deduced from the hu-
man ASPSs described to have arisen primarily within the cranial
vault (Bodi et al., 2009; Das et al., 2012) or cardiac muscle (Luo
et al., 2008). Instead of confirming eithermuscle or neural origins,
our experiments with the Prx1 lineage argue that some mesen-
chymal progenitor, possibly pericyte/endothelial in character,
provides one potential cell of origin distinct from either previ-
ously considered lineage. Because pericytes are ubiquitous
throughout the body, the specific locations of tumors could not
be explained by the availability of a cell of origin alone. However,
a pericyte cell of origin in humans could explain the occasional
ASPS tumor reported to arise in an unusual anatomic location.
We interpret the anatomic location of mouse tumors induced
by expression of ASPSCR1-TFE3 as circumstantial evidence of
a preference for high environmental lactate. While this predilec-
tion for origin within the brain in the mouse is not recapitulated in
human ASPSs, all the tissues that play common host to human
ASPS are also thought to be high lactate tissues, such as skeletal
muscle, cardiac muscle, and brain. Most human ASPSs arise in
the skeletal muscle of active adolescents and young adults, a
host tissue with high lactate shuttling. Among all sarcomas,
ASPS is the most frequently (per its low prevalence) either met-
astatic or primary to the brain (Fox et al., 2009). While the prev-
alence of ASPS comprises 1% of all sarcomas, it is the most
common among primary or metastatic cardiac sarcomas in clin-
ical series as well (Agaimy et al., 2012; Kumar et al., 2011). Inter-
estingly, evidence from different experimental approaches has
shown that the heart can get up to 60% of its energy from lactate
oxidation (Gertz et al., 1988; Gladden, 2008; Stanley, 1991).
While ASPS is not strictly considered to arise in the kidney—
another high lactate tissue—a special subset of renal cell carci-
nomas express and are thought to be driven by the ASPSCR1-
TFE3 fusion gene and other TFE3 fusions (Argani et al., 2001).
Much of ASPS biology has actually been inferred from studies
in a clear cell carcinoma cell line that expresses ASPSCR1-
TFE3 (Ishiguro et al., 2004).
Some other information can be gleaned regarding lactate in
the microenvironment from prior attempts to directly xenograft
human ASPSs into the subcutaneous flanks of immunocompro-
mised mice. Attempts with 12 different tumors yielded four suc-
cesses at a latency of 8–9 months; three of those successes
derived from lung or lymph node metastases (Vistica et al.,
2009).While these data argue that ASPS can grow in host tissues
lacking overtly high lactate, growth may be less efficient in those
settings and may only be possible in select subclones.
Others have shown that lactate can contribute to angiogenesis
(Semenza, 2008; Sonveaux et al., 2008). In glycolytic glioma tu-
mor cells in vitro, lactate exposure increased HIF1a levels inde-
pendent of hypoxia by inhibiting HIF1a proline hydroxylation,
Figure 8. ASPSCR1-TFE3-Induced Mouse Tumors Express Hypoxia Genes in the Absence of Hypoxia and Respond to Exogenous Lactate
(A) Explanatory diagram of the pathway by which either hypoxia or imported lactate can decrease 2-oxoglutarate-mediated Hif1a hydroxylation and degradation
(Lu et al., 2002, 2005).
(B) Photomicrographs of pimonidazole-treated Rosa26-LSL-AT3/CreER mouse tumor and kidney tissue sections stained with immunohistochemistry against pi-
monidazole adducts (above; brown depicts presence of hypoxia) and Hif1a (below), demonstrating nuclear Hif1a, but no hypoxia in tumors, and Hif1a correlating
to hypoxia in normal renal tubules. Scale bars represent 10 mm.
(C) Broad Institute gene set enrichment analysis for the established Harris hypoxia gene list in theRosa26-LSL-AT3/CreERmouse tumor (mASPS) to muscle RNAseq
comparison, showing upregulation of many ostensibly hypoxia-driven genes in the tumors.
(D) Representative photomicrographs of immunohistochemistry against Ki67, indicating proliferating nuclei (brown) or Cd31, indicating vascular endothelial cells
(brown) after 2 weeks of lactate or saline administration to Rosa26-LSL-AT3/CreER mice bearing tumors. Scale bars represent 10 mm.
(E) Chart of the mean ± SD of the ratio of Ki-67-positive tumor cell nuclei to total tumor cell nuclei between the two groups (n = 5 lactate, n = 7 saline controls).
(legend continued on next page)
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et al., 2002, 2005). Others have shown that oxidative tumor cells
in vitro activate HIF1a via importation of lactate (De Saedeleer
et al., 2012). i.p. lactate administration in mice has enhanced
xenografted tumor metastasis and vascularity (Bonuccelli
et al., 2010).
ASPS has long been known to be highly vascular and to ex-
press many angiogenic factors, such as HIF1a (Lazar et al.,
2007; Vistica et al., 2009). We have now added to that observa-
tion the confirmation that ASPS is also normoxic. ASPSs express
high levels of lactate transporters that associate with lactate
import (Mct1 and Cd147) but not export (Mct4) and have abun-
dant mitochondria. Not only do tumors form in areas of high
lactate flux both in ourmodel and in humans, but providing exog-
enous lactate also increased angiogenesis and tumor cell prolif-
eration. Human cell lines known to express ASPSCR1-TFE3
proliferated in response to exogenous lactate and increased in
nuclear HIF1a.
Several cancer metabolism investigations have emphasized
the poor prognostic impact of hypoxia and high lactate, but
these also typically associate with transitions to more metaboli-
cally quiescent cellular states (Brizel et al., 2001; Walenta et al.,
1997, 2004). This is not so with ASPS, which oxidatively metab-
olizes lactate and increases proliferation in response to exoge-
nous lactate.
For years, scientists have understood HIF1a to be induced by
hypoxia (Semenza, 2012). In a similar light, lactate was also long-
considered to be elevated only in hypoxia. Both paradigms are
shifting. There is an abundance of evidence that suggests that
lactate is the primary intermediate in whole body metabolism,
as is best described by the lactate shuttle (Brooks, 2002).
Further, in vitro studies within the last year have shown lactate
to be a powerful driver of HIF1a induction in normoxic conditions
(De Saedeleer et al., 2012). We were able to test directly the de-
gree to which increasing lactate in normoxia is an angiogenic
signaling molecule driving tumorigenesis in vivo.
To conclude, ASPS is a deadly and rare tumor that portends a
poor prognosis. In our efforts to characterize this particular tu-
mor and open the door for metabolic treatments, we have shown
that the tumor microenvironment can impact tumor formation
and angiogenesis, specifically in regard to the role of lactate.
EXPERIMENTAL PROCEDURES
Mice
All mousework was performedwith the approval of the University of Utah insti-
tutional animal care and use committee and in accordance with international
legal and ethical norms. The EWSR1-ATF1, SS18-SSX2, and LacZ mice
were previously described (Haldar et al., 2007; Soriano, 1999; Straessler
et al., 2013), as were Rosa26-CreER and Prx1-CreERT2 mice (Badea et al.,
2003; Hasson et al., 2007). The full length cDNA of type 2 ASPSCR1-TFE3
was reverse transcribed from total RNA isolated from a human ASPS.
The Rosa26-LSL-AT3 targeting vector was electroporated into R1 mouse
embryonic stem cells, which were selected, screened, and microinjected(F) Chart of the mean ± SD of the ratio of the linear vessel perimeter to total tum
(G and H) Charts presenting mean ± standard deviation of the relative viability of A
ASPS-1 (at 72 hr, H) in increasing concentrations of sodium lactate (n = 3 for eac
(I) Western blots showing increased nuclear HIF1awhen exposed to 20mMsodium
and 1 mM in ASPS-1 cells.
860 Cancer Cell 26, 851–862, December 8, 2014 ª2014 Elsevier Inc.into blastocysts. Please see the Supplemental Experimental Procedures for
additional details.
Clinical
With the approval of the University of Utah institutional review board and in
accordance with all international legal and ethical standards, fresh surgical
specimens from consenting patients were banked and stored, then analyzed
after annotation with histopathological, molecular, and clinical data. Please
see the Supplemental Experimental Procedures for additional details.
Transcriptome Analysis
Sequencing was performed on an Illumina HiSeq 2000 (Illumina) using a 50
cycle single end read after mRNA capture by the Ribo-Zero method. The
OverdispersedRegionScanSeqs script in the USeq package (Nix et al., 2008)
calculated the expression levels of ENSEMBL genes in FPKM values. USeq
also discovers differentially expressed genes between two RNA-seq libraries
by calling the DESeq R package (Anders and Huber, 2010).
Gene Expression Omnibus (GEO) data were normalized by DChip (Li and
Hung Wong, 2001). GSEA was performed with Broad Institute software (Moo-
tha et al., 2003; Subramanian et al., 2005). The Harris hypoxia gene set is
curated by the Broad Institute (Harris, 2002), as is MitoCarta, including the
original 1,098 mouse genes, whose proteins localize to the mitochondria,
and their 1,013 human homologs (Pagliarini et al., 2008). Gene ontology anal-
ysis was performed with GO-Elite software (Zambon et al., 2012). Please see
the Supplemental Experimental Procedures for additional details.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the sequencing
data reported in this paper is GSE54729.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and one table and can be found with this article online at http://dx.doi.org/
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